Brief: Antengene Corp Says U.S. FDA Ind Clearance For Phase I Perform Trial Of ATG-031 In Patients With Advanced Solid Tumors Or B-NHL
18/05/2023 02:27
May 18 (Reuters) - Antengene Corporation Ltd 6996.HK :
* U.S. FDA IND CLEARANCE FOR PHASE I PERFORM TRIAL OF
ATG-031 IN
PATIENTS WITH ADVANCED SOLID TUMORS OR B-NHL
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106